Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Atherosclerosis ; 168(2): 271-82, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12801610

RESUMO

Oxidized low-density lipoprotein (oxLDL) exhibits many atherogenic effects, including the promotion of monocyte recruitment to the arterial endothelium and the induction of scavenger receptor expression. However, while atherosclerosis involves chronic inflammation within the arterial intima, it is unclear whether oxLDL alone provides a direct inflammatory stimulus for monocyte-macrophages. Furthermore, oxLDL is not a single, well-defined entity, but has structural and physical properties which vary according to the degree of oxidation. We tested the hypothesis that the biological effects of oxLDL will vary according to its degree of oxidation and that some species of oxLDL will have atherogenic properties, while other species may be responsible for its inflammatory activity. The atherogenic and inflammatory properties of LDL oxidized to predetermined degrees (mild, moderate and extensive oxidation) were investigated in a single system using human monocyte-derived macrophages. Expression of CD36 mRNA was up-regulated by mildly- and moderately-oxLDL, but not highly-oxLDL. The expression of the transcription factor, proliferator-activated receptor-gamma (PPARgamma), which has been proposed to positively regulate the expression of CD36, was increased to the greatest degree by highly-oxLDL. However, the DNA binding activity of PPARgamma was increased only by mildly- and moderately-oxLDL. None of the oxLDL species appeared to be pro-inflammatory towards monocytes, either directly or indirectly through mediators derived from lymphocytes, regardless of the degree of oxidation.


Assuntos
Antígenos CD36/metabolismo , Lipoproteínas LDL/química , Lipoproteínas LDL/farmacologia , Macrófagos/metabolismo , Monócitos/metabolismo , Receptores Citoplasmáticos e Nucleares/metabolismo , Fatores de Transcrição/metabolismo , Antígenos CD36/genética , Diferenciação Celular , Células Cultivadas , Citocinas/metabolismo , DNA/metabolismo , Ácidos Graxos/análise , Humanos , Mediadores da Inflamação/metabolismo , Peróxidos Lipídicos/análise , Linfócitos/metabolismo , Monócitos/citologia , RNA Mensageiro/metabolismo , Receptores Citoplasmáticos e Nucleares/genética , Fatores de Transcrição/genética
2.
Br J Nutr ; 89(5): 607-16, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12720581

RESUMO

There has been much recent interest in the cardiovascular benefits of dietary isoflavones. The aim of the present in vitro studies was to investigate potential anti-thrombogenic and anti-atherogenic effects of the isoflavones genistein and daidzein in platelets, macrophages and endothelial cells. Pre-treatment with either isoflavone inhibited collagen-induced platelet aggregation in a dose-dependent manner. In a macrophage cell line (RAW 264.7) activated with interferon gamma plus lipopolysaccharide, both isoflavones were found to inhibit NO production and tumour necrosis factor alpha (TNF-alpha) secretion dose-dependently, but they did not affect mRNA levels for inducible nitric oxide synthase and cyclo-oxygenase-2. Both isoflavones also dose-dependently decreased monocyte chemoattractant protein-1 secretion induced by TNF-alpha in human umbilical vein endothelial cells. Compared with daidzein, genistein exerted greater inhibitory effects for all parameters studied. The present data contributes to our knowledge on the molecular mechanisms by which isoflavones may protect against coronary artery disease. Further studies are required to determine whether the effects of isoflavones observed in the current in vitro studies are relevant to the aetiology of coronary artery disease in vivo.


Assuntos
Arteriosclerose/prevenção & controle , Endotélio Vascular/efeitos dos fármacos , Genisteína/farmacologia , Isoflavonas/farmacologia , Macrófagos/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Análise de Variância , Animais , Arteriosclerose/metabolismo , Linhagem Celular , Células Cultivadas , Quimiocina CCL2/metabolismo , Ciclo-Oxigenase 2 , Relação Dose-Resposta a Droga , Endotélio Vascular/metabolismo , Humanos , Isoenzimas/metabolismo , Ativação de Macrófagos , Macrófagos/metabolismo , Proteínas de Membrana , Camundongos , Óxido Nítrico/metabolismo , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo II , Prostaglandina-Endoperóxido Sintases/metabolismo , Fator de Necrose Tumoral alfa/biossíntese , Fator de Necrose Tumoral alfa/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA